RxDoctor Payments DataLook up a doctor →

Tamam Mohamad

Interventional Cardiology · Detroit, MINPI 1457687584

Payments from drug & device makers

$959,887in general payments, 2019–2025

Across 1,469 payments — averaging $653.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$226K
  • Novo Nordisk$207K
  • Johnson & Johnson$167K
  • Lilly USA, LLC$139K
  • Medtronic$78K
  • Bayer$61K
  • plus $82K from 54 others

What the payments were for

  • Consulting fees$19,0632%
  • Speaking & faculty fees$867,94790%
  • Travel & lodging$20,0582%
  • Food & beverage$34,5934%
  • Education$4350%
  • Other$17,7922%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim210$225,552
Novo Nordisk122$207,063
Johnson & Johnson154$166,855
Lilly USA, LLC126$138,652
Medtronic(2 entities)99$77,800
Bayer42$61,464
Novartis104$18,237
Angiodynamics, Inc.7$17,948
Venclose Inc.9$10,541
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)57$10,173
Tactile Systems Technology Inc44$8,229
Eli Lilly1$5,000
GSK78$1,441
Boston Scientific52$1,298
Kestra Medical Technology Services, Inc.25$872
Pfizer58$824
Merck43$727
Recor Medical Inc14$655
Cardinal Health 200 LLC34$618
Cardiovascular Systems Inc.10$560
Terumo Medical Corporation6$546
AstraZeneca29$536
Abbott12$512
Amgen27$399
E.r. Squibb & Sons, L.L.C.23$362
Actelion Pharmaceuticals US, Inc.5$266
Inari Medical, Inc.1$251
Cathworks, Inc.2$244
Astellas Pharma US Inc3$175
Innova Vascular Inc.1$160
Kiniksa Pharmaceuticals International, PLC4$148
Abiomed1$135
Cordis US CORP.8$128
Inspire Medical Systems, Inc.1$124
Ablative Solutions, Inc.1$123
Truvic Medical, Inc.1$100
Impulse Dynamics (USA) Inc.5$96
Penumbra, Inc.3$94
Baxter Healthcare1$91
American Regent1$82
United Therapeutics Corporation3$63
Bridgebio Pharma, Inc.3$56
Cardiva Medical, Inc.2$54
Lexicon Pharmaceuticals, Inc.3$54
Kiniksa Pharmaceuticals, Ltd.3$52
Cvrx, Inc.3$51
Amarin Pharma, Inc.3$46
Alnylam Pharmaceuticals Inc.2$45
Daiichi Sankyo Inc.2$42
Preventice Services, LLC1$33
Bard Peripheral Vascular, Inc.3$33
Getinge USA Sales, LLC1$31
Edwards Lifesciences1$19
Philips North America LLC1$19
Convatec Inc.1$19
Corcept Therapeutics1$18
EKOS Corporation1$18
Ultragenyx Pharmaceutical Inc.1$18
Imperative Care, Inc1$18
Chiesi USA, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$959,887 in reported general payments places this provider in the 95th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$1,223,857
Medicare patients
645
Services billed
15,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan297$257,215
XareltoRivaroxaban299$218,805
JardianceEmpagliflozin232$175,903
EliquisApixaban182$143,486
BrilintaTicagrelor83$61,531
KerendiaFinerenone31$26,824
OzempicSemaglutide27$26,237
Repatha SureclickEvolocumab36$22,416
FarxigaDapagliflozin Propanediol24$21,201
JanuviaSitagliptin Phosphate20$13,671
Ranolazine ErRanolazine210$12,400
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,886
Isosorbide Mononitrate ErIsosorbide Mononitrate696$7,205
ClopidogrelClopidogrel Bisulfate603$6,874
Cilostazol376$5,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$18,237$257,215297 claims
Johnson & JohnsonXarelto$166,855$218,805299 claims
Boehringer IngelheimJardiance$225,552$175,903232 claims
PfizerEliquis$824$143,486182 claims
AstraZenecaBrilinta, Farxiga$536$82,733107 claims
BayerKerendia$61,464$26,82431 claims
Novo NordiskOzempic$207,063$26,23727 claims
MerckJanuvia$727$13,67120 claims
GSKTrelegy Ellipta$1,441$8,88614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →